CONTACT US: Contact info
|
Citation |
Lu DY, Zhu PP, Wu HY, Yarla NS, Xu B, Ding J, Lu TR. Cent. Nerv. Syst. Agents Med. Chem. 2019; 19(1): 15-23. |
|
Affiliation |
Shanghai University, Shanghai 200444. China. |
|
Copyright |
(Copyright © 2019, Bentham Science Publishers) |
|
DOI |
|
PMID |
30644350 |
|
Abstract |
Suicide is still a major event of human mortality (2 %) worldwide. However, no magic bullet (high efficacy drug targeting suicide categories >80%) has been developed due to limitation of biological knowledge of suicide events and pharmacological progress. Influenced by complex environmental factors, social-economic conditions, diverse suicidal-associated genes/molecules, drug development grows slowly and narrow-spectra. In search of pharmaceutical options against human suicide, an accelerating pace of transition from psychoanalysis (cognitive, behavior and emotional) into psycho-morphology disciplines (genetics/image) through neurobiology study (neural-transmitter, receptors and different neural-locations) is more potential now. Neural-psychiatric association study may profoundly impact on pharmacotherapy for suicide prevention and therapeutics. Nonetheless, neural biological knowledge and technical advances for etiological complexity of human suicide (a hybrid of genetics, genomics, epigenetics, proteomics, metabolomics, neural/brain image/circuits versus cognitive, behaviors, emotional and social processing ability) don't allow immediate medical fruits in the clinic and high-quality drug developments in pharmaceutical markets. A great deal of neurobiological study may achieve clinical paradigms (modern diagnosis and magic bullet pharmacotherapy). In the future, clinical suicide prediction and therapeutics by new medications may be in full-swing. Language: en |
|
Keywords |
Mental disorders; clinical pharmacology; drug development; human suicide; modern diagnosis; neural pathogenesis; neural-imaging; psycho-morphology; psychoanalysis |